A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).
Cancer
DRUG: ARGX-110
Incidence and grading of AEs, Change from baseline in incidence and grading of AEs according to the Common Terminology Criteria for Adverse Event (NCI-CTCAE) Version 4.03, measured at screening, Day 1, Day 8, Day 15, Day 42, thereafter every 42 days until Day 378
Pharmacokinetic profile of ARGX110 by Cmax, Change from baseline in Measurement of drug concentration in the blood, measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378|Pharmacokinetic profile of ARGX110 by AUC, Change in Measurement of drug concentration in the blood, measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378|Biomarkers CD70 immunohistochemistry (IHC), Change in Measurement of concentration in tumor tissue, measured at Screening, Day 42, and thereafter every 42 days until day Day 378
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).